# Royalty Pharma plc (RPRX)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/RPRX/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 630.58M | $ 295.00M | $ 760.54M | $ 8.96B | $ 6.89B |
| 2025 | $ 2.44B | $ 789.38M | $ 2.55B | $ 8.95B | $ 6.48B |
| 2024 | $ 2.38B | $ 902.86M | $ 2.91B | $ 7.61B | $ 6.95B |
| 2023 | $ 2.55B | $ 1.23B | $ 3.23B | $ 6.14B | $ 6.53B |
| 2022 | $ 2.50B | $ 47.85M | $ 2.40B | $ 7.12B | $ 5.63B |
| 2021 | $ 2.72B | $ 736.64M | $ 2.40B | $ 7.10B | $ 5.78B |
| 2020 | $ 2.70B | $ 1.24B | $ 2.59B | $ 5.82B | $ 4.82B |
| 2019 | $ 2.34B | $ 3.03B | $ 2.15B | $ 6.24B | $ 6.11B |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 1.30 |
| Liabilities / Eq | 1.43 |
| Current Ratio | 2.66 |

## Debt coverage

| Indicator | Value |
| --- | --- |
| Gross Debt / Earnings | 8.66 |
| Gross Debt / FCF | 73.05 |

## Other views

- [Metrics](https://sponda.capital/en/RPRX.md)
- [Charts](https://sponda.capital/en/RPRX/charts.md)
- [Compare](https://sponda.capital/en/RPRX/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-13.